Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Change in Accured Expenses (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Change in Accured Expenses data on record, last reported at $5.1 million in Q4 2023.

  • For Q4 2023, Change in Accured Expenses rose 219.77% year-over-year to $5.1 million; the TTM value through Dec 2023 reached $10.1 million, up 17.82%, while the annual FY2025 figure was $8.0 million, 177.24% up from the prior year.
  • Change in Accured Expenses reached $5.1 million in Q4 2023 per CGEM's latest filing, down from $5.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.2 million in Q3 2023 and bottomed at -$2.8 million in Q2 2023.
  • Average Change in Accured Expenses over 4 years is $1.6 million, with a median of $1.6 million recorded in 2021.
  • The widest YoY moves for Change in Accured Expenses: up 13304.76% in 2021, down 645.12% in 2021.
  • A 4-year view of Change in Accured Expenses shows it stood at -$21000.0 in 2020, then surged by 13304.76% to $2.8 million in 2021, then crashed by 42.91% to $1.6 million in 2022, then skyrocketed by 219.77% to $5.1 million in 2023.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $5.1 million in Q4 2023, $5.2 million in Q3 2023, and -$2.8 million in Q2 2023.